Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis

Table 6 Univariate and multivariate analyses for overall survival and disease-free survival of the 73 rectal patients with clinical LPNM who underwent TME + LPND

Variables	Overall survival				Disease-free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR(95%CI)	P	HR(95%CI)	P	HR(95%CI)	P	HR(95%CI)	P
Gender: male/female	1.01 (0.36–2.83)	0.993			1.19 (0.54–263)	0.660
Age	1.03 (0.98–1.08)	0.314			1.00 (0.97–1.04)	0.953
BMI (Kg/m²)	1.02 (0.86–1.21)	0.801			0.95 (0.83–1.08)	0.404
Pre-nCRT CEA level	1.01 (0.99–1.03)	0.495			1.01 (1.00–1.03)	0.026	1.01 (0.97–1.03)	0.262
Pre-nCRT CA19-9 level	1.01 (0.99–1.01)	0.093			1.00 (0.99–1.01)	0.158
Post-nCRT CEA level	1.09 (0.95–1.26)	0.220			1.04 (0.95–1.13)	0.399
Post-nCRT CA19-9 level	1.01 (0.99–1.01)	0.135			1.01 (0.99–1.01)	0.183
Histology	3.50 (1.24–9.89)	0.018	2.21 (0.75–6.48)	0.150	1.81 (0.95–3.29)	0.076
Distance from AV	1.16 (0.91–1.50)	0.238			1.01 (0.81–1.23)	0.939
T stage: T3–4/T1–2	3.41 (0.70–8.00)	0.109			2.22 (0.89–5.52)	0.087
N stage: N1–2/N0	8.00 (1.80–35.54)	0.006	7.41 (1.63–33.75)	0.010	2.41 (1.05–4.93)	0.044	2.04 (0.93–5.10)	0.087
LPN metastasis	4.42 (1.54–12.74)	0.006	3.82 (1.19–12.25)	0.024	2.67 (1.18–6.02)	0.018	2.33 (1.02–5.14)	0.044
Mesorectal LN harvested	1.02 (0.98–1.07)	0.299			1.02 (0.98–1.01)	0.388
LPN harvested	1.01 (0.94–1.09)	0.742			1.01 (0.96–1.06)	0.730
Operative time	1.00 (0.99–1.01)	0.980			1.00 (0.99–1.01)	0.635
Estimated bleeding	1.00 (0.99–1.01)	0.682			1.00 (1.00–1.01)	0.089
Postoperative complications	0.73 (0.20–2.67)	0.633			0.84 (0.34–2.10)	0.714

BMI body mass index, AV anal verge, LPN, lateral pelvic lymph node, LN lymph nodes, LPNM lateral pelvic lymph node metastasis, LPND lateral pelvic lymph node dissection, TME total mesorectal excision

ISSN: 1471-2482